Clinical Trial Update: JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial update reports a JAK1 inhibitor, ivarmacitinib, being studied to overcome immunotherapy resistance in triple-negative breast cancer, wi…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Ivarmacitinib

Snippet

Sponsor: Fudan University | Conditions: Triple Negative Breast Cancer (TNBC), Metastatic Breast Cancer | Phase 2 | Status: NOT_YET_RECRUITING